Inclusion Criteria:

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study

- Age > 50 years

- Patient related considerations

- Able to maintain follow-up for at least 24 months.

- Women must be postmenopausal without a period for at least one year.

- Hgb A1C < 6

- Diagnosed with Age-related Macular Degeneration (ARMD) with active subfoveal
choroidal neovascular membrane (CNVM), new or recurrent

- Visual acuity 20/60 to 20/400

- Lesion size < 12 Disc Area

- Submacular hemorrhage less than 75% of total lesion

- Submacular fibrosis less than 25% of total lesion

- Candidate for intravitreal Lucentis

Exclusion Criteria:

- Prior enrollment in the study

- Pregnancy (positive pregnancy test) or lactation

- Any other condition that the investigator believes would pose a significant hazard to
the subject if the investigational therapy were initiated

- Participation in another simultaneous medical investigation or trial

- CNVM within 1 mm from the disc margin

- Photodynamic Therapy (PDT) within 3 months

- Anti-VEGF therapy within 6 weeks

- Intravitreal or subtenon's Kenalog within 6 months

- Intraocular surgery within 3 months or expected in the next 6 months

- Current or planned participation in other experimental treatments for wet AMD

- Other concurrent retinopathy or optic neuropathy

- Other causes of CNVM, i.e. myopic degeneration or ocular histoplasmosis (POHS)

- Significant media opacity precluding adequate view of the fundus for exam,

- photography or OCT

- History of radiation therapy to the head or study eye

- Systemic anticoagulation with coumadin

- Head tremor or h/o claustrophobia precluding positioning for proton irradiation

- Inability to maintain steady fixation with either eye

- Diabetes mellitus requiring treatment

- History of Malignancy treated within 5 years

- Allergy to Fluorescein dye